• Indications
  • Open Access TIMES Journals
Login Register
Login Register
Indications
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Open Access TIMES Journals
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Oncology · Hematology

Oncology · Hematology

Case Reports
Expert Opinions
Congress News
E-Learning
Webinar
Faculty
healthbook TIMES
Homepage >
Oncology · Hematology >
Articles

Determinants of late metastases in renal cell carcinoma

Genitourinary Cancer
Share:
Do you want to read an article? Please log in or register.
Register for Free
Remember me
Forgot password? Click here

Related content

Genitourinary Cancer
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial
Int J Cancer
Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D, Suárez C, Négrier S, Lee JL, Santini D, Bedke J, Staehler M, Kollmannsberger C, Choueiri TK, Motzer RJ, Burgents JE, Xie R, Okpara CE, Powles T
doi: 10.1002/ijc.35288
Genitourinary Cancer
[(89)Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial
Lancet Oncol
Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, Scott AM, van Praet C, Bailly C, Önal B, Aksoy T, Merkx R, Schuster DM, Lee ST, Pandit-Taskar N, Fan AC, Allman P, Schmidt K, Tauchmanova L, Wheatcroft M, Behrenbruch C, Hayward CRW, Mulders P
doi: 10.1016/S1470-2045(24)00402-9
Genitourinary Cancer
Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease
Eur Urol
Linehan WM, Pinto CA, Liu Y, Choo K, Gautam R, Fox C, Roy A, Li M, Bosan R, Nielsen D, Ryan B, Blake Z, Reynolds K, Rompre-Brodeur A, Pinto PA, Vocke C, Gurram S, Ball MW, Perini R, Srinivasan R
doi: 10.1016/j.eururo.2025.03.002
Genitourinary Cancer
Spontaneous regression of metastatic clear cell renal cell carcinoma: A report of a rare case and a review of the literature
Urol Case Rep
Mullasseril A, Lam AB, Mitta A, Morton D, McIntosh A, Patel S, Thai T, Annan A, Ayanambakkam A
doi: 10.1016/j.eucr.2024.102868
Genitourinary Cancer
Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial
Ann Oncol
Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juárez V, Rini BI, Larkin J, Nolè F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ
doi: 10.1016/j.annonc.2024.12.008
Genitourinary Cancer
Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis
Lancet Oncol
Huang RS, Chow R, Benour A, Chen D, Boldt G, Wallis CJD, Swaminath A, Simone CB 2nd, Lock M, Raman S
doi: 10.1016/S1470-2045(24)00731-9
Genitourinary Cancer
IMPACT OF 3D-PRINTED MODELS FOR SURGICAL PLANNING IN RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS. A RANDOMISED MULTICENTER CLINICAL TRIAL
J Urol
Rivero-Belenchón I, Congregado Ruíz CB, Gómez Ciriza G, Gómez Dos Santos V, Burgos Revilla FJ, Medina López RA
doi: 10.1097/JU.0000000000004425
Genitourinary Cancer
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
Lancet
Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ
doi: 10.1016/S0140-6736(24)01758-6
Genitourinary Cancer
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial
Lancet Oncol
Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B
doi: 10.1016/S1470-2045(25)00032-4
  • Contact us
  • About us
  • Privacy Policy & Disclaimer
  • Online Media 2025 Data
  • Imprint
healthbook is a registered trademark. Copyright © 2025 healthbook